Title: Introduction to Anti-Human NTRK1 Monoclonal Antibody (1A717)
The NTRK1 gene, also known as the neurotrophic tyrosine kinase receptor type 1, encodes for the TrkA protein, which is a member of the neurotrophic receptor tyrosine kinase family. This protein plays a crucial role in the development and maintenance of the nervous system. Dysregulation of NTRK1 has been linked to various neurological disorders, making it an important research target. In this article, we will discuss the structure, activity, and application of Anti-Human NTRK1 Monoclonal Antibody (1A717).
Structure of Anti-Human NTRK1 Monoclonal Antibody (1A717)
Anti-Human NTRK1 Monoclonal Antibody (1A717) is a monoclonal antibody that specifically targets the extracellular domain of the TrkA protein. It is produced by hybridoma technology using mouse myeloma cells fused with spleen cells from mice immunized with recombinant human TrkA protein. The antibody has a molecular weight of approximately 150 kDa and belongs to the IgG1 subclass.
Activity of Anti-Human NTRK1 Monoclonal Antibody (1A717)
The primary function of Anti-Human NTRK1 Monoclonal Antibody (1A717) is to block the activity of the TrkA protein. This is achieved by binding to the extracellular domain of TrkA and preventing its interaction with its ligands, nerve growth factor (NGF) and brain-derived neurotrophic factor (BDNF). This inhibition of TrkA activity can lead to a decrease in downstream signaling pathways, such as the MAPK/ERK and PI3K/AKT pathways, which are involved in cell proliferation, survival, and differentiation.
Application of Anti-Human NTRK1 Monoclonal Antibody (1A717)
Anti-Human NTRK1 Monoclonal Antibody (1A717) has a wide range of applications in both research and clinical settings. In research, it is commonly used as a tool to study the role of TrkA in various cellular processes and diseases. For example, it has been used to investigate the involvement of TrkA in neurodegenerative diseases, such as Alzheimer’s and Parkinson’s disease. It has also been used to study the role of TrkA in cancer, as NTRK1 gene fusions have been identified in various types of cancer, including breast, lung, and colon cancer.
In clinical settings, Anti-Human NTRK1 Monoclonal Antibody (1A717) has shown promising results in the treatment of diseases associated with dysregulated TrkA signaling. One of the most notable applications is in the treatment of pain. NGF, the ligand for TrkA, has been implicated in the development of chronic pain. By blocking the activity of TrkA, Anti-Human NTRK1 Monoclonal Antibody (1A717) has shown potential as a therapeutic agent for chronic pain management.
Furthermore, Anti-Human NTRK1 Monoclonal Antibody (1A717) has also been investigated as a potential treatment for cancer. In preclinical studies, it has been shown to inhibit tumor growth and induce cell death in cancer cells that express TrkA. This makes it a promising candidate for targeted cancer therapy, particularly in cases where NTRK1 gene fusions are present.
Conclusion
In conclusion, Anti-Human NTRK1 Monoclonal Antibody (1A717) is a valuable tool for studying the role of TrkA in various diseases and has potential therapeutic applications in pain management and cancer treatment. Its specific targeting of the extracellular domain of TrkA makes it a highly specific and effective inhibitor of TrkA activity. Further research and clinical trials are needed to fully explore the potential of this antibody in improving human health.
There are no reviews yet.